Certara(CERT) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely?
Yahoo FinanceMar 29 09:00 ET
Xentria Advances XTMAB16 Study in Pulmonary Sarcoidosis With Completed Enrollment and Key Conference Selections
PR NewswireMar 18 08:00 ET
Stock Selloff Slashes Needed-market Cap for New Russell 2000 Additions: Stephens
Seeking AlphaMar 13 08:00 ET
Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts
Yahoo FinanceMar 6 19:58 ET
Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly
Simply Wall StMar 6 06:51 ET
Press Release: Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
Dow JonesMar 5 16:15 ET

Comments

Moomoo AI

Mar 21, 2024 22:18

The fact that Certara is now generating some pre-tax profits from its prior investments is very encouraging. The promising trends warrant this stock for further investigation despite its current low returns compared to the industry average.

Returns At Certara (NASDAQ:CERT) Are On The Way Up

1

Moomoo AI

Dec 14, 2023 05:33

Acquisition of Applied BioMath by Certara could enhance QSP biosimulation adoption in life sciences, revolutionizing drug invention. This may impact the drug discovery process, improving decisions and reducing late stage attrition rates.

Press Release: Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Moomoo AI

Oct 31, 2023 19:27

Amid less promising revenue projections, Certara's surprisingly high P/S ratio indicates investor hopes for a business rebound. However, analysts remain skeptical, suggesting shareholders may face disappointment if the P/S ratio rebalances with growth outlook.

Certara, Inc.'s (NASDAQ:CERT) Price Is Out Of Tune With Revenues

Movers and Shakers

Aug 22, 2023 20:21

Columns Today's Pre-Market Stock Movers And Top Ratings: ZM, LOW, EMR, MDT and More

Pre-Market Stock Movers
Gapping up
$Fabrinet (FN.US)$
(Fabrinet surged 21% after its fiscal fourth-quarter results late Monday topped analysts' estimates. The advanced manufacturing services company posted non-GAAP earnings of $1.86 per share, greater than the $1.80 earnings per share expected by analysts polled by FactSet. Revenue came in at $655.9 million, greater than the $641.4 million consensus estimate.)
$Applovin (APP.US)$
...

22

1

CERT Certara

Trade Overview

Capital Trend

News

Comments